Subtype
Renal Pelvis and Ureter Carcinoma
CI-CAN-00003809Explore in graph →
48 active trials1 evidence items
- NCIt
- C7515
Loading cancer entity…
Subtype
CI-CAN-00003809Explore in graph →
Clinical trials
105 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (8)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07793240 | Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC) | not yet recruiting | — | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07751796 | OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma | not yet recruiting | N/A | 15 | Yonsei UniversityOTHER | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07720921 | Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )(LUXUS0701) | not yet recruiting | Phase 2 | 20 | Peking University First HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07591805 | HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC(HERO-UTUC) | not yet recruiting | Phase 2 | 49 | RenJi HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07584733 | Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma | not yet recruiting | Phase 2 | 50 | RenJi HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07557563 | Flexible Ureterorenoscopy for Surveillance of Upper Tract Urothelial Carcinoma | not yet recruiting | N/A | 10 | Chinese University of Hong KongOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07504939 | Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma | not yet recruiting | — | 36 | Peking University First HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07412171 | NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC(NECTAR) | not yet recruiting | Phase 2 | 40 | Peking University Third HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06798246 | HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively:A Perspective Cohort Study | not yet recruiting | — | 200 | Peking University First HospitalOTHER | 0 | Jan 29, 2025 | clinicaltrials |
| NCT06469229 | Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria | not yet recruiting | — | 1,200 | Changhai HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06472752 | Neoadjuvant Radiotherapy for High-risk UTUC(LUXUS07) | not yet recruiting | — | 40 | Peking University First HospitalOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05810623 | Single-Dose Intravesical Chemotherapy After Diagnostic URS(MINERVA) | not yet recruiting | Phase 3 | 394 | David D'AndreaOTHER | 1 | Apr 12, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials